Aleksandra Jezela-Stanek

Prof. Aleksandra Jezela-Stanek

National Institute of Tuberculosis and Lung Diseases, Department of Genetics and Clinical Immunology
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Justyna PaprockaJustyna Paprocka
Justyna Paprocka
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
ATAnna Tylki-Szymanska
Anna Tylki-Szymanska
SGStephanie Grunewald
Stephanie Grunewald
Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post-translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations in the following genes: ALG13, DOLK, DPAGT1, SLC35A2, ST3GAL3, PIGA, PIGW, ST3GAL5. On brain neuroimaging, atrophic changes of the cerebellum and cerebrum are frequently seen. Brain malformations particularly in the group of dystroglycanopathies are reported. Despite the growing number of CDG patients in the world and often neurological symptoms dominating in the clinical picture, the number of performed screening tests eg transferrin isoforms is systematically decreasing as broadened genetic testing is recently more favored. The aim of the review is the summary of selected neurological symptoms in CDG described in the literature in one paper. It is especially important for pediatric neurologists not experienced in the field of metabolic medicine. It may help to facilitate the diagnosis of this expanding group of disorders. Biochemically, this paper focuses on protein glycosylation abnormalities.

Verified
Journal Article
Open access
PDF file
ULUrszula Lechowicz
Urszula Lechowicz
SRStefan Rudzinski
Stefan Rudzinski
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
Sabina JanciauskieneSabina Janciauskiene
Sabina Janciauskiene
Joanna Chorostowska-WynimkoJoanna Chorostowska-Wynimko
Joanna Chorostowska-Wynimko
Alpha-1-antitrypsin (AAT), an acute-phase protein encoded by the SERPINA1 gene, is a member of the serine protease inhibitor (SERPIN) superfamily. Its primary function is to protect tissues from enzymes released during inflammation, such as neutrophil elastase and proteinase 3. In addition to its antiprotease activity, AAT interacts with numerous other substances and has various functions, mainly arising from the conformational flexibility of normal variants of AAT. Therefore, AAT has diverse biological functions and plays a role in various pathophysiological processes. This review discusses major molecular forms of AAT, including complex, cleaved, glycosylated, oxidized, and S-nitrosylated forms, in terms of their origin and function.

1 May 2016 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
ECElżbieta Ciara
Elżbieta Ciara
DPDorota Piekutowska-Abramczuk
Dorota Piekutowska-Abramczuk
JTJoanna Trubicka
Joanna Trubicka
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
EPEwa Pronicka
Ewa Pronicka

22 June 2021 in Children
Verified
Journal Article
Open access
PDF file
DWDorota Wesół-Kucharska
Dorota Wesół-Kucharska
DRDariusz Rokicki
Dariusz Rokicki
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
Mitochondrial diseases are a heterogeneous group of diseases resulting from energy deficit and reduced adenosine triphosphate (ATP) production due to impaired oxidative phosphorylation. The manifestation of mitochondrial disease is usually multi-organ. Epilepsy is one of the most common manifestations of diseases resulting from mitochondrial dysfunction, especially in children. The onset of epilepsy is associated with poor prognosis, while its treatment is very challenging, which further adversely affects the course of these disorders. Fortunately, our knowledge of mitochondrial diseases is still growing, which gives hope for patients to improve their condition in the future. The paper presents the pathophysiology, clinical picture and treatment options for epilepsy in patients with mitochondrial disease.

22 November 2020 in Genes
Verified
Journal Article
Open access
PDF file
KSKarolina M Stepien
Karolina M Stepien
ECElżbieta Ciara
Elżbieta Ciara
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
Fucosidosis is a neurodegenerative disorder which progresses inexorably. Clinical features include coarse facial features, growth retardation, recurrent upper respiratory infections, dysostosis multiplex, and angiokeratoma corporis diffusum. Fucosidosis is caused by mutations in the FUCA1 gene resulting in α-L-fucosidase deficiency. Only 36 pathogenic variants in the FUCA1 gene are related to fucosidosis. Most of them are missense/nonsense substitutions; six missense and 11 nonsense mutations. Among deletions there were eight small and five gross changes. So far, only three splice site variants have been described—one small deletion, one complete deletion and one stop-loss mutation. The disease has a significant clinical variability, the cause of which is not well understood. The genotype–phenotype correlation has not been well defined. This review describes the genetic profile and clinical manifestations of fucosidosis in pediatric and adult cases.

17 February 2012 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AJAleksandra Jezela-Stanek
Aleksandra Jezela-Stanek
MKMarzena Kucharczyk
Marzena Kucharczyk
MPMagdalena Pelc
Magdalena Pelc
KCKrystyna Chrzanowska
Krystyna Chrzanowska
MKMałgorzata Krajewska-Walasek
Małgorzata Krajewska-Walasek